<DOC>
	<DOCNO>NCT00819351</DOCNO>
	<brief_summary>The purpose study investigate intramuscular PEG-asparaginase administer either six two week interval day 92 8 month diagnosis patient non-HR ALL result equal probability Event Free Survival</brief_summary>
	<brief_title>ALL2008 Protocol Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase</brief_title>
	<detailed_description>20 % child ALL still fail cure . The ALL-2008 protocol treatment research protocol aim improve overall outcome Nordic child adolescents ALL comparison ALL-2000 protocol previous NOPHO protocol . The specific primary objective randomise study : To test intramuscular PEG-asparaginase administer either six two week interval day 92 8 month diagnosis patient non-HR ALL result equal probability EFS . As secondary endpoint asparaginase antibody production toxicity include allergic reaction treatment-arms analyse</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Childhood ALL All mandatory biological data available6 Written inform consent obtain Bilineage ALL Pretreatment glucocorticosteroids antileukemic agent 1 week ALL predisposition syndromes Previous cancer Off protocol administration additional chemotherapy induction therapy Sexually active female use contraception No allergic reaction PEG Asparaginase</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>acute lymphoblastic leukemia</keyword>
	<keyword>child</keyword>
	<keyword>PEG-Asparaginase</keyword>
	<keyword>EFS</keyword>
	<keyword>efficacy</keyword>
	<keyword>childhood acute lymphoblastic leukemia</keyword>
</DOC>